Katherine Goodrich - Jun 12, 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Jun 12, 2025
Transactions value $
$0
Form type
4
Date filed
6/16/2025, 04:05 PM
Previous filing
Nov 15, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Goodrich Katherine Director C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Scott Sieckert, Attorney-in-Fact 2025-06-16 0002044770

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +4.54K $0.00 4.54K Jun 12, 2025 Common Stock 4.54K $40.95 Direct F1
transaction TARS Restricted Stock Units Award $0 +2.95K $0.00 2.95K Jun 12, 2025 Common Stock 2.95K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.